Retail Crowd

Complete British News World

PAION AG Announced subscription The correct capital will increase to over 8 million. On & Published Provisional, Unstated Essential Consolidated Financial Pfizers 2020 from March 19, 2021

DGAP-News: PAION AG / Keyword (s): Preliminary Results / Capital Increase
PAION AG Announced subscription The correct capital will increase to over 8 million. AT AND PUBLISHED, UNTESTED MAJOR GROUP FINANCIAL FIGURES 2020

19.03.2021 / 20:16
The issuer is responsible for the content of the notice.

Distributed or published in the United States or in any country, individually or directly, any publication may be illegal.

PAION AG Announced subscription The correct capital will increase to over 8 million. AT AND PUBLISHED, UNTESTED MAJOR GROUP FINANCIAL FIGURES 2020

Guaranteed capital increase on subscription rights less than 8 8 million

– Group Financial Statistics for 2020 Forecast, Sales Increase and Positive Annual Results in 2020

– Successfully launched in Japan, China and the United States

Aachen, March 19, 2021 – The Board of Directors of the specialized pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) (“PAION” or “Company”) today decided to raise the company’s share capital from 66,241,493. 5,095,499.00 to 71 71,336,992.00, in exchange for cash contributions by granting subscription rights to existing shareholders by issuing 5,095,499 equivalent value-bearing shares with a proportional amount of share capital of புதிய 1.00 each (“new shares”). The subscription price is 1.5 1.54 per share.

PAION will receive a total publishing revenue of less than 8 8 million from the rights issue. In addition, PAION will receive 7 7.5 million for the third installment of its financial agreement with the European Investment Bank (EIP).

PAION will use the net income generated by the increase in capital to selectively launch its product portfolio in selected European countries and for public enterprise purposes.

Business Partner Activities
In Japan, licensee Mundiparma successfully launched Anerom’s first commercial product sale in mid-2020.(R) (Remimasolam) started. At the end of 2020, Mundiparma announced that there would be aneurysms in about 400 hospitals in Japan(R) Was listed. According to Mundiparma, this is almost 100% beyond their original target. Mundiparma also supports experiments initiated by several investigators.

In China, licensee Yichang Humanwell began successfully marketing in the third quarter of 2020. At the end of 2020, Yichang Humanwell announced the introduction of Ruyama(R) (Remimasolam) in hospitals in 31 Chinese provinces.

READ  Corona: This is life in countries with high Govt vaccinations

Remimosol sales in Japan and China in 2020 were 2. 2.6 million. Based on the agreed percentages of net sales, this results in a license fee of 0. 0.3 million, of which ரோ 0.1 million. May be approved for sale in fiscal year 2020. PAION and Mundipharma have agreed to calculate the license fee after the balance date. The relevant amendment to the agreement is currently being made, based on which the remaining 0. 0.2 million license fee will be approved for sale in fiscal 2021.

In the United States, licensee Acacia Pharma began selling BYFAVO (TM) (Remimozolam) in January 2021, recently announcing that this release is going to be very special.

Preliminary Integrated Statistics 2020:
Preliminary (unaudited) panel figures for FY20 (IFRS) are in line with the forecast:

According to preliminary figures, sales rose to 19 19.7 million in FY20, from 8 8 million in the previous year, primarily as a result of landmark payments related to gaining market approvals for the US, Japan and Remix. Expansion of the license area for Remimosol by six additional countries in China and Southeast Asia, which expired in January 2020 with Hana Farm, the licensee.

Expenditure on research and development was 10. 10.3 million (previous year: 13 13.1 million) and was mainly related to the EU Phase III study on general anesthesia.

Expenditure on public administration and sales, mainly in connection with the establishment of a supply chain and the commercialization of Remimasolam, increased by 2.5 2.5 million compared to the previous year to 7 7.5 million during the year under review.

The annual surplus in fiscal year 2020 was 2. 2.2 million, compared to the previous year’s deficit of 7 7 million.

So the preliminary consolidated annual figures are in line with the forecast. PAION AG plans to release its annual financial statements for fiscal year 2020 on March 30, 2021 after 5 p.m.

READ  They are already setting the price for the fall of the UK

With excellent milestones such as the first approvals of Remimosol in the major pharmaceutical markets of the US, Japan and China, 2020 marks a turning point for PAION, followed by successful market launches by our partners in these countries“PAION AG CEO Dr. Jim Phillips commented.”GIAPREZA is the latest licensor of intensive care products(R) And XERAVA(R) Confirms our decision to set up our own infrastructure to commercialize our product portfolio in selected European countries. Remimazole in short sedation is expected soon, with European approval, and we expect to be able to market a third product in Europe. The introduction of these three products has gone well in other major pharmaceutical markets. We therefore expect similar strong interest from hospitals in Europe to use these new products and address medical needs that have not yet been met. “

Abdelkhani Omari, Chief Financial Officer, PAION AG, added: “Capital increase and the third installment of EIP loan total gross income. 15 15.3 million, with financial resources based on current planning, ensures that cash flow reaches the first half of 2022. “

###

About PAION
PAION AG is a listed specialty pharmaceutical company that aims to develop and market innovative active ingredients for use in outpatient and hospital anesthesia, anesthesia and intensive care medicine. The leading combination of PAION is Remimasolam, an intravenous, ultra-short-acting and easily controlled benzodiazepine anesthetic and anesthetic. Remimozolam is a joint venture in many markets outside of Europe. Remimosol is approved for brief anesthesia in the United States and China and for general anesthesia in Japan and South Korea.

PAION seeks approval for FIFA in Europe(R) (Remimasolam) in general anesthesia and short-term anesthesia. In January 2021, the European Pharmaceuticals Organization (CHMP) panel recommended the approval of Bifavo for human use.(R) In a short faint. It is planned, bifao(R) After approval in Europe with GIAPREZA(R), A vasoconstrictor used to treat ineffective hypotension in adults with septic or other distribution shock, despite the use of adequate restorative and catecholamines and other available vasopressor therapies and XERAVA(R) To treat complex intra-abdominal infections in adults.

READ  Vanguard expands ESG product range with ESG Global All Cap UCITS ETF - ETF-News

PAION aims to be a leading specialist pharmaceutical company in the field of anesthesia and complex care medicine by bringing to market new products that benefit patients, physicians and health partners.

PAION is headquartered in Aachen and has another location in Cambridge (United Kingdom).

Contact PAION:
Ralph Benner
Vice President Investor Relations / Public Relations
PAION AG
Hyustras25
52078 Aachen
Phone. +49 241 4453-152
Email [email protected]
www.paion.com

Disclaimer:

This release contains some perspective statements about PAION AG. These reflect the best ratings and assumptions of PAION AG’s knowledge as of the date of this announcement and include some risks, uncertainties and other factors. If the circumstances underlying the company’s assumptions change, this can lead to significant deviations from the actual results and actions implicitly or explicitly expected decisions and actions. Given these risks, uncertainties and other factors, the recipients of this publication are warned not to place unnecessary credibility on these perspective statements. PAION AG accepts no obligation to update or update such perspective statements in order to reflect future events or developments.

This issue is not a bid or request for the purchase of securities in the United States or any other country. This publication or its contents may not be used as a basis for privilege in any country. PAION AG’s securities may not be sold or issued in the United States until they have been registered, or are required to be registered under the United States Securities Act of 1933, as amended (“Securities Act”). PAION AG’s securities are not registered under the Securities Act.

03/19/2021 Publication of a Corporate News / Financial News, Disseminated by DGAP – Service of EQS Group AG.
The issuer is responsible for the content of the notice.

DGAP distribution services include regulatory reporting, corporate / financial news and news releases.
Media archive at http://www.dgap.de